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Abstract
Background Patients with psoriasis who have an inade-
quate response to one biologic may benefit from switching
to a new biologic, such as ixekizumab, a high affinity
monoclonal antibody that selectively targets interleukin
(IL)-17A.
Objective Our aim was to assess the response to ixek-
izumab in patients with moderate-to-severe plaque psoria-
sis who did not respond adequately to etanercept using a
post-hoc analysis in two phase III studies.
Methods For the subanalyses in two phase III trials
(UNCOVER-2 and -3), non-response was defined by
either failure to have a static physician global assess-
ment (sPGA) of 0/1 in UNCOVER-2 or failure to have
at least 75% improvement in psoriasis area and severity
index (PASI 75) in UNCOVER-3 at Week 12 of each
study. Non-responders treated with twice-weekly etan-
ercept 50 mg in the first 12 weeks received two injec-
tions of placebo at Week 12 (4-week wash-out period),
followed by ixekizumab every 4 weeks (Q4W) for
Weeks 16–60. Non-responders to placebo in the first
12 weeks were administered ixekizumab 160 mg at
Week 12, followed by ixekizumab Q4W for Weeks
16–60.
Results After switching to ixekizumab Q4W, a substantial
proportion of patients with moderate-to-severe psoriasis
who did not respond to etanercept experienced rapid and
durable improvement in all efficacy evaluations. Among
sPGA 0/1 (UNCOVER-2) and PASI 75 (UNCOVER-3)
non-responders to etanercept, 73.0% achieved sPGA 0/1
and 78.2% achieved PASI 75, respectively, after
12 weeks of ixekizumab treatment. Safety profiles in
patients switched from etanercept to ixekizumab were
similar to those in patients switched from placebo to
ixekizumab.
Conclusion Patients who were non-responders to etaner-
cept after 12 weeks, as defined by failure to meet sPGA 0/1
(UNCOVER-2) or PASI 75 (UNCOVER-3), achieved high
levels of response 12 weeks after switching to ixekizumab.
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Key Points
Alternative therapies are needed for patients with
psoriasis who must discontinue a tumor necrosis
factor alpha (TNF-a) inhibitor due to limited
efficacy, loss of efficacy, or adverse reactions.
In patients switched to ixekizumab following non-
response to etanercept, a TNF-a inhibitor, we
observed a favorable response in the majority of
patients.
In both UNCOVER-2 and -3, safety profiles were
comparable in placebo non-responders and
etanercept non-responders after switching to
ixekizumab.
1 Introduction
There are several emerging biologic therapies for the
treatment of psoriasis, providing patients with more options
for the management of this chronic and at times debilitat-
ing disease [1–4]. Availability of new agents raises the
question of how prior treatment might affect future thera-
pies. Patients who do not respond optimally to one biologic
therapy may benefit from switching to a biologic that acts
through a different mechanism. Indeed, in the ACCEPT
trial, psoriasis area and severity index (PASI) response
rates of patients who were non-responders to etanercept
during the induction period improved after switching to
ustekinumab, even though response rates after 12 weeks
were lower among these patients compared with those
given ustekinumab during the induction period [5]. On the
other hand, a Danish observational study found no asso-
ciation between prior treatment with tumor necrosis factor
alpha (TNF-a) inhibitors and response to subsequent
therapy with ustekinumab [6].
Ixekizumab is a high affinity monoclonal antibody that
selectively targets interleukin (IL)-17A. This drug has
previously been reported to have rapid and lasting efficacy
in the treatment of moderate-to-severe plaque psoriasis in
three phase III clinical trials (UNCOVER-1, -2, and -3)
[1, 2]. Two of these trials (UNCOVER-2 and -3) included
an etanercept treatment arm during the induction period
(Weeks 0–12). In this post-hoc subanalysis of UNCOVER-
2 and -3 trials, we examined the safety and efficacy of
ixekizumab in patients switched to ixekizumab every
4 weeks (Q4W) following non-response (NR) to 12 weeks
of treatment with etanercept or placebo. For completeness
of the analysis in trials with differing study designs, we
looked at two different criteria for defining non-responders:
failure to reach the static physician global assessment
(sPGA) 0/1 (UNCOVER-2) or failure to reach 75%
improvement in PASI (PASI 75; UNCOVER-3).
2 Methods
2.1 Patients
An investigational review board at each site approved
study protocols and informed consent forms, and all
patients signed informed consent prior to undergoing
study-related procedures. UNCOVER-2 (NCT01597245)
was registered on May 10, 2012 and UNCOVER-3
(NCT01646177) was registered on July 18, 2012 with
ClinicalTrials.gov. Complete patient eligibility criteria for
the UNCOVER-2 and -3 trials have been previously
described [1]. Briefly, patients aged 18 years or older were
eligible with a confirmed diagnosis of chronic plaque
psoriasis at least 6 months prior to baseline (randomiza-
tion), at least a moderate disease severity as measured by
clinician-rated measure of sPGA score C3, at least 10%
body surface area (BSA) involvement, and PASI score C12
at both screening and baseline visits. Patients with prior
exposure to etanercept were excluded from these studies.
2.2 Study Design and Treatment Regimens
2.2.1 Induction Period (UNCOVER-2 and -3): Weeks 0–12
During the 12-week placebo- and active-controlled period
in each of these phase III trials, patients were randomized
at a 2:2:2:1 ratio stratified by center to one of the following
treatment groups: ixekizumab 80 mg every 2 weeks
(Q2W) or Q4W following a starting dose of 160 mg,
etanercept 50 mg twice weekly, or placebo.
2.2.2 Weeks 12–60 (UNCOVER-2)
In UNCOVER-2, failure to meet sPGA 0/1 at Week 12 was
the pre-specified criterion defining non-response to treat-
ment. All sPGA 0/1 non-responders, regardless of induc-
tion treatment group, were switched to ixekizumab 80 mg
Q4W. Therefore, UNCOVER-2 data support the analysis
of patients who were non-responders to etanercept based on
sPGA definition. All patients who received etanercept in
the induction period and did not achieve sPGA 0/1 at Week
12 underwent a 4-week washout period where placebo
injections were given at Week 12, and patients were started
on ixekizumab 80 mg Q4W at Week 16. All patients who
received placebo in the induction period who did not
achieve sPGA 0/1 at Week 12 were given ixekizumab
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160 mg at Week 12, and ixekizumab 80 mg Q4W starting
at Week 16.
2.2.3 Weeks 12–60 (UNCOVER-3)
In UNCOVER-3, all patients, regardless of induction
treatment group and sPGA response at Week 12, were
switched to ixekizumab 80 mg Q4W. Therefore,
UNCOVER-3 data support the analysis of patients who
were non-responders to etanercept based on PASI 75 def-
inition. All patients who received etanercept in the induc-
tion period (regardless of response at Week 12) underwent
a 4-week washout period where placebo injections were
given at Week 12, followed by ixekizumab Q4W starting at
Week 16. All patients who received placebo in the induc-
tion period were given ixekizumab160 mg at Week 12 and
ixekizumab 80 mg Q4W starting at Week 16. Safety data
for UNCOVER-3 is based on the data reported at the time
of the Week 60 interim database lock; therefore, some
events occurred beyond 60 weeks.
2.3 Statistical Analyses
For the analyses described here, we looked at two defini-
tions of NR. In UNCOVER-2, the pre-specified definition
of NR based on FDA guidance was failure to meet sPGA
0/1 at Week 12. In a post-hoc subanalysis of UNCOVER-3,
NR was defined as failure to achieve PASI 75 by Week 12.
Non-responder imputation (NRI) was used for categor-
ical variables for missing data. Change from baseline PASI
and percent improvement in PASI used last observation
carried forward (LOCF), and treatment comparisons in the
induction period for these variables were done using an
analysis of covariance model, including treatment, pooled
center, and baseline (Week 0) PASI value in the model.
Safety analyses were conducted on all patients who
received at least one dose of assigned study treatment
during the study period. An adverse event is considered a
treatment-emergent adverse event if it first occurs or
worsens following the start of treatment during a study
period. Incidence rates (IRs) were based on the number of
events per 100 person-years of exposure, with entire time
on treatment considered the exposure time rather than time
until the first event. If a patient had multiple events, all
events were counted.
3 Results
In both UNCOVER-2 and -3, baseline characteristics of
etanercept responders were generally comparable to those
of non-responders, except for weight, which was
numerically higher in the non-responder (as defined by
either sPGA 0/1 or PASI 75) versus responder groups
(Table 1).
At Week 12 in UNCOVER-2, 64% of etanercept-treated
patients, 27.1% of ixekizumab Q4W-treated patients, and
16.8% of ixekizumab Q2W-treated patients were sPGA 0/1
non-responders. Among the etanercept-treated patients who
did not reach sPGA 0/1 at Week 12 and switched to ixek-
izumab Q4W (n = 200), 73.0% had an sPGA 0/1, 83.5%
had a PASI 75, 57.0% had a PASI 90, and 22.0% had a
PASI 100 after 12 weeks of treatment with ixekizumab
Q4W (Week 28) (Fig. 1a). After 44 weeks (Week 60) of
treatment with ixekizumab Q4W, among induction-period
sPGA 0/1 non-responders to etanercept, 71.0% achieved an
sPGA 0/1, 82.5% achieved a PASI 75, 68.5% achieved a
PASI 90, and 43.5% achieved a PASI 100 (Fig. 1a;
Table 2). sPGA 0/1, PASI 75, 90, and 100 responses for
placebo-treated patients who were sPGA 0/1 non-responders
at Week 12 and treated with ixekizumab from Weeks 12–60
(48 weeks of treatment with ixekizumab Q4W) are pre-
sented in Fig. 1b and Table 2. At Week 60, the percent
improvement in PASI and percentages of patients achieving
nail psoriasis area and severity index (NAPSI) and psoriasis
scalp severity index (PSSI) scores of 0 were also similarly
high in non-responders to both placebo and etanercept after
switching to ixekizumab (Table 2).
At Week 12 in UNCOVER-3, 46.6% of etanercept-
treated patients, 15.8% of ixekizumab Q4W-treated
patients, and 12.7% of ixekizumab Q2W-treated patients
were PASI 75 non-responders. Among the etanercept-
treated patients who were PASI 75 non-responders at
Week 12 and switched to ixekizumab Q4W (n = 165),
78.2% had a PASI 75, 58.8% had a PASI 90, and 27.3%
had a PASI 100 after 12 weeks of treatment with ixek-
izumab Q4W (Week 28) (Fig. 2a). As described previously
with UNCOVER-2, long-term efficacy was also observed
in UNCOVER-3, with 77.6% of etanercept PASI 75 non-
responders achieving a PASI 75, 67.9% achieving a
PASI 90, and 43.0% achieving a PASI 100 after 44 weeks
(Week 60) of treatment with ixekizumab Q4W (Fig. 2a;
Table 2). PASI 75, 90, and 100 responses for placebo-
treated patients who were PASI 75 non-responders at
Week 12 and treated with ixekizumab from Weeks 12 to 60
(48 weeks of treatment with ixekizumab Q4W) are also
presented in Fig. 2b and Table 2. As in UNCOVER-2, in
UNCOVER-3 the percent improvement in PASI, and per-
centages of patients achieving NAPSI and PSSI scores of 0
for patients who switched to ixekizumab after non-response
to etanercept or placebo were similarly high at Week 60
(Table 2).
Overall, safety profiles, represented as incidence rates of
treatment-emergent adverse events (TEAEs) of any sever-
ity, serious adverse events (AEs), or AEs leading to
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discontinuation in the two subgroups of non-responders to
placebo or etanercept in UNCOVER-2 or -3 were generally
comparable after switching to ixekizumab (Table 3). Fur-
thermore, there were also no outstanding differences in
incidence rates of adverse events of special interest,
including injection-site reactions, infections, Candida
infections, and inflammatory bowel disease in either sub-
group in either trial after switching to ixekizumab
(Table 3).
4 Discussion
In both trials, high percentages of patients who were sPGA
0/1 (UNCOVER-2) or PASI 75 (UNCOVER-3) etanercept
non-responders during the induction period achieved sPGA
0/1, PASI 75, 90, and 100 after 12 weeks and maintained
this response through 44 weeks following the switch to
ixekizumab Q4W, demonstrating a potential long-term
benefit in switching to ixekizumab following non-response










Age, years 42.9 (12.6) 46.7 (12.6) 45.3 (14.0) 46.5 (13.8)
Male, n (%) 89 (67.4) 126 (63.0) 139 (68.1) 121 (73.3)
Weight, kg 87.6 (17.6) 96.7 (24.1) 86.0 (20.7) 100.0 (25.7)
Psoriasis duration, years 19.4 (12.4) 18.6 (12.3) 17.6 (11.4) 18.9 (12.5)
Percentage of BSA
involved
26.7 (14.9) 23.4 (14.8) 28.4 (16.6) 28.2 (18.8)
sPGA 3.5 (0.6) 3.5 (0.6) 3.5 (0.6) 3.6 (0.6)
PASI 19.1 (6.2) 18.7 (6.4) 20.6 (7.8) 20.9 (8.7)
PSSI 21.3 (16.5) 18.9 (14.3) 19.7 (13.6) 20.1 (13.2)
NAPSI 28.5 (18.7) 31.7 (21.5) 25.3 (21.2) 25.5 (18.5)
All data presented as mean (SD) unless otherwise stated
BSA body surface area, NAPSI nail psoriasis severity index, NR non-responder, PASI psoriasis area and severity index, PSSI psoriasis scalp
severity index, SD standard deviation, sPGA static physician global assessment
Among patients who had at least one dose of ixekizumab or placebo in the Week 12-60 period of each study
Fig. 1 UNCOVER-2: sPGA and PASI response rates through Week
60 in Week 12 sPGA 0/1 non-responders. sPGA 0/1, PASI 75,
PASI 90, and PASI 100 response rates among patients in
UNCOVER-2 who were switched to ixekizumab Q4W if they were
Week 12 sPGA 0/1 non-responders to etanercept (a) or placebo (b).
Response rates for all patients treated with etanercept (a) or placebo
(b) during the first 12 weeks have been previously reported and are
provided for reference [1]. ETN etanercept, ETN-NR/IXEQ4W
etanercept Weeks 0–12, placebo at Week 12, and 80 mg ixekizumab
every 4 weeks for Weeks 16–60, NR sPGA 0/1 non-responder at
Week 12, PASI psoriasis area and severity index, PBO placebo, PBO-
NR/IXEQ4W placebo Weeks 0-12 and 80 mg ixekizumab every
4 weeks for Weeks 16–60 after a starting dose of 160 mg at Week 12,
sPGA static physician global assessment
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Table 2 Psoriasis outcomes after 12 and 60 weeks in each study

























sPGA 0/1 (NRI), n (%) 4 (2.4) 129 (36.0) 13 (6.7) 159 (41.6) 112 (72.3) 142 (71.0) 132 (78.1) 114 (69.1)
PASI 75 (NRI), n (%) 4 (2.4) 149 (41.6) 14 (7.3) 204 (53.4) 129 (83.2) 165 (82.5) 147 (87.0) 128 (77.6)
PASI 90 (NRI), n (%) 1 (0.6) 67 (18.7) 6 (3.1) 98 (25.7) 109 (70.3) 137 (68.5) 133 (78.7) 112 (67.9)
PASI 100 (NRI), n (%) 1 (0.6) 19 (5.3) 0 28 (7.3) 70 (45.2) 87 (43.5) 93 (55.0) 71 (43.0)
NAPSI = 0 (NRI),
n (%)a
10 (8.8) 24 (10.5) 5 (4.3) 24 (10.2) 57 (53.3) 58 (45.0) 65 (60.7) 50 (49.5)
PSSI = 0 (NRI), n (%)b 11 (7.3) 144 (44.7) 16 (9.1) 178 (51.1) 103 (73.0) 130 (71.4) 130 (83.9) 111 (74.5)
Change from baseline
PASI (LOCF)c




6.8 (2.1) 58.9 (1.5) 14.1 (1.8) 68.8 (1.3) 92.5 (17.2) 88.2 (37.9) 93.0 (17.1) 87.2 (23.4)
ETN etanercept, ETN-NR/IXEQ4W etanercept Weeks 0–12, placebo at Week 12, and ixekizumab every 4 weeks for Weeks 16–60, LOCF last
observation carried forward, NAPSI nail psoriasis severity index, NR non-responder, NRI non-responder imputation, PASI psoriasis area and
severity index, PBO placebo, PBO-NR/IXEQ4W placebo Weeks 0-12 and ixekizumab every 4 weeks for Weeks 16–60 after a starting dose of
160 mg at Week 12, PSSI psoriasis scalp severity index, sPGA static physician global assessment
a Only patients with NAPSI[0 at baseline were included in this analysis
b Only patients with PSSI[0 at baseline were included in this analysis
c Week 12 results are reported as least squares (LS) mean (standard error) and Week 60 results are reported as LS mean (standard deviation)
Fig. 2 UNCOVER-3: sPGA and PASI response rates through Week
60 in Week 12 PASI 75 non-responders. sPGA 0/1, PASI 75,
PASI 90, and PASI 100 response rates among patients in
UNCOVER-3 who were switched to ixekizumab Q4W if they were
Week 12 PASI 75 non-responders to etanercept (a) or placebo (b).
Response rates for all patients treated with etanercept (a) or placebo
(b) during the first 12 weeks have been previously reported and are
provided for reference [1]. ETN etanercept, ETN-NR/IXEQ4W
etanercept Weeks 0–12, placebo at Week 12, and 80 mg ixekizumab
every 4 weeks for Weeks 16–60, NR PASI 75 non-responder at Week
12, PASI psoriasis area and severity index, PBO placebo, PBO-NR/
IXEQ4W placebo Weeks 0-12 and 80 mg ixekizumab every 4 weeks
for Weeks 16–60 after a starting dose of 160 mg at Week 12, sPGA
static physician global assessment
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to etanercept. Responses to etanercept did not appear to be
impacted substantially by differences in baseline charac-
teristics, with the potential exception of weight. This is
generally consistent with previously established findings,
where greater percentages of patients in lower weight (or
body mass index [BMI]) categories had higher responses
than patients in higher weight (or BMI) categories,
although weight category cut points varied by study [7, 8].
There is currently variability in guidance regarding what
defines a non-response that warrants change in treatment.
sPGA 0/1 or PASI 75 has frequently been the treatment
goal in phase III clinical trials; however, non-response has
often been defined as failure to achieve PASI 50. Fur-
thermore, current guidelines by the European Consensus
Program [9] recommend remaining on the same treatment
regimen unless the following conditions apply: reduction in
PASI of\50%, or a reduction in PASI of at least 50% and
\75% combined with a DLQI (Dermatology Life Quality
Index) score[5. The results of the present analysis suggest
that PASI 75 or sPGA 0/1 non-responders may indeed
benefit from switching, although neither of these trials had
a comparator group that continued receiving etanercept to
determine the full level of benefit from switching over
time.
Of note, it has been recommended that clinicians should
wait four times the terminal biologic half-life to ensure that
the first biologic has been cleared from the body before
starting a second biologic [10]. Interestingly, a recent
consensus report from the Transitioning Therapies
program, created by dermatologists from 33 countries,
suggests using a washout period when patients are
switching biologic therapies for safety concerns but not
when switching due to lack of efficacy [11]. In
UNCOVER-2 and -3, five times the terminal half-life was
deemed appropriate for a drug under development. Hence,
the response to ixekizumab without a washout in etaner-
cept-treated patients was not assessed.
There are several limitations to these analyses. These
studies were not designed to directly compare outcomes in
etanercept non-responders versus placebo non-responders
switched to ixekizumab Q4W. Additionally, while patients
and investigators in UNCOVER-2 remained blinded
through Week 60, patients and investigators in
UNCOVER-3 were not blinded after the first 12 weeks of
treatment, potentially resulting in higher responses after
Week 12 in that trial. Another potential limitation is that
some patients may require more than 12 weeks to achieve
sPGA 0/1 or PASI 75 in response to etanercept; therefore,
it is conceivable that with longer exposure to etanercept,
some of the non-responders might have become respon-
ders. The ixekizumab dosing regimen currently approved
in several markets for the treatment of moderate-to-severe
plaque psoriasis includes a 160-mg starting dose at Week 0
followed by 12 weeks of 80 mg ixekizumab every 2 weeks
[9]. It is possible that responses following the switch to
ixekizumab may have been higher if this induction dosing
regimen had been used in the etanercept non-responders at
Week 16.
Table 3 Adverse events Weeks 12–60a of UNCOVER-2 and -3
UNCOVER-2 (sPGA 0/1 NR) UNCOVER-3 (PASI 75 NR)
PBO/IXEQ4W (N = 155)
(PY = 134.3) n (IR)
ETN/IXEQ4W (N = 200)
(PY = 174.4) n (IR)
PBO/IXEQ4W (N = 169)
(PY = 233.0) n (IR)
ETN/IXEQ4W (N = 165)
(PY = 217.0) n (IR)
TEAE 125 (93.0) 158 (90.6) 137 (58.8) 125 (57.6)
Mild 42 (31.3) 56 (32.1) 50 (21.5) 40 (18.4)
Moderate 65 (48.4) 85 (48.8) 68 (29.2) 71 (32.7)
Severe 18 (13.4) 17 (9.8) 19 (8.2) 14 (6.5)
SAE 12 (8.9) 9 (5.2) 20 (8.6) 13 (6.0)
AE leading to
discontinuation
8 (6.0) 8 (4.6) 8 (3.4) 7 (3.2)
Injection site
reactions
17 (12.7) 24 (13.8) 16 (6.9) 11 (5.1)
Infections 86 (64.0) 111 (63.7) 93 (39.9) 85 (39.2)
Candida 1 (0.7) 3 (1.7) 0 0
Crohn’s disease 1 (0.7) 0 1 (0.4) 0
Ulcerative colitis 0 0 0 0
AE adverse event, ETN etanercept, ETN-NR/IXEQ4W etanercept Weeks 0-12, placebo at Week 12, and ixekizumab every 4 weeks for Weeks
16–60, IR incidence rate/100 patient years, NR non-responder, PBO placebo, PBO-NR/IXEQ4W placebo Weeks 0-12 and ixekizumab every
4 weeks for Weeks 16–60 after a starting dose of 160 mg at Week 12, PY patient years, SAE serious AE, TEAE treatment-emergent AE
a Safety data for UNCOVER-3 are based on the data reported at the time of the Week 60 interim database lock; therefore, some events occurred
beyond 60 weeks
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Like the results found in the present analyses, the
ACCEPT study showed that many patients who were non-
responders to etanercept experienced a PASI 75 response
after switching to ustekinumab [5]. However, in contrast to
the ACCEPT study, in both UNCOVER-2 and -3, patients
who switched to ixekizumab Q4W after non-response to
etanercept had similarly high responses (84 and 78% had a
PASI 75; 57% and 59% had a PASI 90) as patients treated
with ixekizumab Q4W as induction therapy (78 and 84%
had a PASI 75; 60 and 65% had a PASI 90) following
12 weeks of treatment [1, 5]. This supports the notion that
switching an etanercept non-responder to a biologic that
inhibits IL-17A may be a clinically beneficial strategy. Of
note, there are currently no guideline recommendations
regarding optimal sequence of therapies for patients with
psoriasis and whether patients would benefit from a faster/
higher level of clearance at early stages of treatment.
5 Conclusions
Patients with moderate-to-severe plaque psoriasis who
were non-responders to etanercept therapy after 12 weeks,
as defined by different criteria (i.e., sPGA 0/1 and
PASI 75), had high levels of clinical responses after being
switched to 80 mg ixekizumab Q4W. This response was
attained quickly and maintained through Week 60 in two
phase III trials, with similar safety profiles for both placebo
non-responders and etanercept non-responders who swit-
ched to ixekizumab.
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